v3.26.1
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenue $ 139,514 $ 666,655
Cost of sales 30,695 14,115
Research and development expenses: 95,472 88,937
Selling, general, and administrative expense 28,777 48,090
Other segment income (expense) 5,939  
Net income (loss) (9,491) 518,646
Reportable Segment    
Segment Reporting Information [Line Items]    
Revenue 139,514 666,655
Cost of sales 30,695 14,115
Selling, general, and administrative expense 28,777 48,090
Other segment income (expense)   3,133
Net income (loss) (9,491) 518,646
Reportable Segment | Employee and benefit expenses    
Segment Reporting Information [Line Items]    
Research and development expenses: 38,056 39,910
Reportable Segment | Facility and other research and development expenses    
Segment Reporting Information [Line Items]    
Research and development expenses: 18,044 29,089
Reportable Segment | Direct COVID-19 Vaccine    
Segment Reporting Information [Line Items]    
Research and development expenses: 34,255 7,277
Reportable Segment | Direct CIC and influenza vaccines    
Segment Reporting Information [Line Items]    
Research and development expenses: 2,853 12,504
Reportable Segment | Direct other vaccine development programs    
Segment Reporting Information [Line Items]    
Research and development expenses: $ 2,264 $ 157